Underwriting AgreementUnderwriting Agreement • June 22nd, 2017 • AveXis, Inc. • Biological products, (no disgnostic substances) • New York
AveXis, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”) an aggregate of 3,575,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 536,250 additional shares (the “Optional Shares”) of Common Stock, par value $0.0001 (“Stock”) of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”.
